The Cancer Letter

Inside information on cancer research and drug development

ClinicalTrials & Tribulations

Menin inhibitors emerge as new treatment for advanced AML

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

The world of cancer treatments continues to evolve, and for those diagnosed with blood cancers, a new option can be found in menin inhibitors—the latest form of targeted therapy in advanced acute leukemia. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Ghayas Issa, MD
Associate professor of leukemia, The University of Texas MD Anderson Cancer Center
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

Marina Konopleva joins Break Through Cancer

Marina Konopleva, director of the Leukemia Program and co-director of the Blood Cancer Institute at the Montefiore Einstein Comprehensive Cancer Center, has joined Break Through Cancer, a collaborative medical research foundation that supports teams of scientists as they advance treatments for some of the world’s deadliest cancers. 
In Brief

MD Anderson’s Boot Walk to End Cancer raises $1.4M

The University of Texas MD Anderson Cancer Center hosted its ninth annual Boot Walk to End Cancer fundraising event on Nov. 2, in the Texas Medical Center. This year, the Boot Walk’s 7,000+ in-person participants and 1,200+ virtual participants from Houston and around the world joined together to raise $1.4 million to support the institution’s mission to end cancer. 
Byline
Ghayas Issa, MD
Associate professor of leukemia, The University of Texas MD Anderson Cancer Center
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account